Divalproex Sodium Tablet, Delayed Release
Product Images NDC 63187-743

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 63187-743). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (B937b05a C544 4ba2 9047 4b3e85f6c164 01)

Chemical structure of divalproex sodium, showing the molecular arrangement including propyl and sodium carboxylate groups.*

FDA Label Image

Comparison Of Percentage Of Patient Separated By Study (B937b05a C544 4ba2 9047 4b3e85f6c164 02)

A bar graph comparing percentage values between placebo (PBO) and Divalproex Sodium (DVPX) groups in two studies labeled Study 1 (YMRS) and Study 2 (MRS). The graph shows higher percentages for Divalproex Sodium in both studies, with Study 1 reaching 60% and Study 2 reaching 58%, while placebo percentages are 26% and 29% respectively.*

FDA Label Image

% Reduction In Cps Rate Vs % Of Patients (B937b05a C544 4ba2 9047 4b3e85f6c164 03)

A cumulative percentage graph comparing the percent reduction in CPS rate between Divalproex Sodium and placebo. The y-axis shows percent reduction in CPS rate from -100% (worsening) to 100% (improvement), and the x-axis shows the percent of patients from 100 to 0. The solid line represents Divalproex Sodium, and the dashed line represents placebo, illustrating greater improvement with Divalproex Sodium.*

FDA Label Image

% Reduction In Cps Rate Vs % Of Patients (B937b05a C544 4ba2 9047 4b3e85f6c164 04)

A cumulative distribution plot showing the percent reduction in CPS rate versus percent of patients for Divalproex Sodium. The graph includes two dose groups, high dose (solid line) and low dose (dashed line). The vertical axis ranges from -100% (worsening) to 100% (improvement), and the horizontal axis shows percent of patients from 0 to 100, illustrating comparative response rates between the two dosing groups.*

FDA Label Image

Mean 4-week Migraine Rates (B937b05a C544 4ba2 9047 4b3e85f6c164 05)

Bar chart showing comparative data between Placebo and Divalproex Sodium in two separate studies labeled Study 1 and Study 2. The vertical axis represents a numeric scale from 0 to 6, with Placebo bars higher than Divalproex Sodium bars in both studies, indicating differences in measured outcomes between treatments.*

FDA Label Image

Company Logo (B937b05a C544 4ba2 9047 4b3e85f6c164 06)

FDA Label Image

63187-742-60 (B937b05a C544 4ba2 9047 4b3e85f6c164 08)

Label for Divalproex Sodium 250 mg delayed release oral tablets, bottle of 60 tablets, by Proficient Rx LP. The label includes dosing form, strength, NDC 63187-742-60, manufacturer Unichem Laboratories Ltd, storage instructions 20°-25°C, and patient medication guide instructions.*

FDA Label Image

63187-743-60 (B937b05a C544 4ba2 9047 4b3e85f6c164 09)

Label for Divalproex Sodium 500 mg delayed-release oral tablets by Proficient Rx LP. The label shows a quantity of 60 tablets, marked as Rx only. It includes detailed tablet description, storage instructions, manufacturer information (Unichem Laboratories, India), and multiple smaller label copies on the right with batch and expiration placeholders.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.